# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-29 (automated, unattended)
**Scope:** Review of latest script outputs in `Analysis/Results/`, snapshot comparison, and web breaking-news check. No existing files were modified.

---

## Headline (read this first)

**The two baseline data pipelines are stale — they last ran on 2026-07-17 (12 days ago).** Everything downstream (trial diffs, PubMed alerts) is frozen at that date, so this run has **no genuinely new trial or publication activity to report** — only what was already captured on the 17th. The gap-analysis and agent-state pipelines are still running daily. Priority action is to re-run the two baseline scripts.

Confidence tags follow the Research Doctrine convention used below: **[Certain]** = read directly from files/verifiable, **[Likely]** = strong inference, **[Guessing]** = gap-filling.

---

## File System Status

| File | Last modified | Age | Status |
|------|---------------|-----|--------|
| `hub_monitor_report.md` | 2026-07-17 | 12 d | **Stale** |
| `clinical_trials_latest.json` | 2026-07-17 | 12 d | **Stale** |
| `pubmed_recent_latest.json` | 2026-07-17 | 12 d | **Stale** |
| `literature_gap_data.json` | 2026-07-18 | 11 d | Aging |
| `literature_gap_report.md` | 2026-07-28 | 1 d | Fresh |
| `agent_state.json` | 2026-07-28 | 1 d | Fresh |
| `Diabetes_Research_Tracker.xlsx` | 2026-07-17 | 12 d | Stale |

- Latest trial snapshot: `clinical_trials_snapshot_2026-07-17.json` — **no snapshots for the last 12 days.** [Certain]
- Latest PubMed snapshot: `pubmed_recent_snapshot_2026-07-17.json` — same gap. [Certain]
- The Jul-17 hub monitor already flagged **827 result files older than 14 days**; that count has only grown. [Certain]

**Interpretation [Likely]:** `hub_monitor.py` and the gap runner still fire on schedule (daily `agent_state.json` backups run through 2026-07-27, gap report refreshed 07-28), but `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py` stopped producing output after 07-17. Something in those two jobs is failing silently or was disabled.

---

## Clinical Trial Changes

Source snapshot: `clinical_trials_latest.json` (2026-07-17). **858 trials** across five categories (T1D Cure & Cell Therapy 152, T1D Immunotherapy 76, T2D Novel Therapies 147, Devices 236, Recently Completed w/ Results 321).

**Snapshot-to-snapshot change (07-16 → 07-17, the last diff available):** +1 new trial, −1 removed, 0 status changes, 0 new results. No newer diff exists. [Certain]

### Phase 3 RECRUITING — key-organization trials to watch [Certain]

| NCT | Sponsor | Therapy / focus |
|-----|---------|-----------------|
| NCT06832410 | Vertex | VX-880 (islet cell therapy) — pivotal Phase 3 |
| NCT04786262 | Vertex | VX-880 safety/efficacy |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly) in T1D |
| NCT07564414 | Novo Nordisk | CagriSema Phase 3 |
| NCT07222332 | Eli Lilly | Baricitinib to preserve beta-cell function (children) |
| NCT07222137 | Eli Lilly | Baricitinib to delay Stage 3 T1D |
| NCT07088068 | Sanofi | Teplizumab head-to-head Phase 3 |

52 Phase 3 recruiting trials total in the snapshot. Both Lilly baricitinib T1D trials and the Sanofi teplizumab trial directly track key therapies on our watchlist.

### Recently posted results worth a look [Certain]

- **NCT06010004 — Eli Lilly, orforglipron long-term safety (T2D)** — results posted 2026-06-30. Key-therapy watchlist hit.
- NCT05610111 — Adaptive Biobehavioral Control closed-loop (posted 2026-07-07).
- NCT05254002 — Bayer combination therapy study (posted 2026-07-13).
- NCT05925920 — Metabolics Pharma ENT-03 (posted 2026-06-01).

---

## PubMed Highlights

Source: `pubmed_recent_latest.json` (2026-07-17, 30-day lookback, 158 unique papers, 16 domains). **Note: this window closed 12 days ago.** [Certain]

### Cross-domain papers (highest value — 12 total) [Certain]

Most notable:
- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: pediatric type 1 diabetes* — spans **AI/ML + Closed Loop AP + Health Equity** (triple-domain; rare). Directly relevant to Tier 1 AI/ML and Epidemiology work.
- **[42419792]** Comparative effects of obesity drugs — **orforglipron + retatrutide + CagriSema** (triple key-therapy).
- **[42458730]** / **[42459212]** Multi-omic BMI/nutrition modelling — **Microbiome + Multi-Omics** (Tier 1 Multi-Omics).
- **[42453334]** Noncoding RNAs for diabetes — **Biomarker + LADA**.

### Key-therapy mentions in the corpus [Certain]

Papers surfaced for orforglipron (incl. PMID 42363271, T2D obesity), retatrutide (42385950), CagriSema (42251856 add-on to basal insulin), baricitinib, teplizumab (**42332392 / 42295172 — expanded Tzield indication**), icodec (42387310), and dapagliflozin (42441491). Note: the pipeline's `therapy_hits` counters all read **0** for this window despite these matches appearing in `papers` — **likely a counter/aggregation bug worth checking** when the script is re-run. [Likely]

### Volume [Certain]

Busiest domains: AI/ML (260 hits), Microbiome (186), T2D GLP-1 New (167), Biomarker (166). Thinnest: GLP-1 Pharmacogenomics (1), Epigenetics (5), Drug Repurposing (8) — consistent with prior windows.

---

## Gap Analysis Summary

Source: `literature_gap_report.md` (2026-07-28, fresh; 30 domains, 435 pairs). **Validation level: BRONZE** per doctrine (single analytic source, expert confirmation pending).

### Top 5 "potentially meaningful" gaps [Certain, as reported — classification is BRONZE]

| Rank | Intersection | Gap Score | Joint pubs |
|------|--------------|-----------|-----------|
| 1 | Treg / CAR-T × Neuropathy | 100.0 | 0 |
| 2 | Beta Cell Regen × Health Equity | 100.0 | 0 |
| 3 | Treg / CAR-T × Health Equity | 100.0 | 0 |
| 4 | Glucokinase × Health Equity | 100.0 | 0 |
| 5 | Gene Therapy × LADA | 100.0 | 0 |

### Alignment with Tier 1 contribution areas

Four of the top five involve **Health Equity** (Doctrine Tier 1 #6, Epidemiological/Disparity analysis) or **Literature Synthesis** (Tier 1 #2) — both areas where the hub is explicitly positioned to contribute with public data and no wet-lab dependency. **Beta Cell Regen × Health Equity** and **Drug Repurposing × Health Equity** (rank 6) are the most actionable: they pair a Tier 1 method (equity/epi analysis) with an emerging-therapy access question, which is a defensible computational-only contribution. [Likely]

Caveat from the report itself: a Gap Score of 100 with 0 joint pubs can reflect terminology mismatch rather than true white space — each must be verified with a direct combined-term PubMed search before any synthesis work.

---

## Breaking News (web check, last ~7 weeks of major items)

Only genuinely significant items flagged:

- **Retatrutide (Lilly) — first Phase 3 T2D + obesity results, ADA June 2026.** Triple-hormone (GIP/GLP-1/glucagon) agonist. HbA1c reductions of 18.5–21.2 mmol/mol vs 8.9 placebo; weight loss 11.5–15.3% vs 2.6%; benefits in OSA and knee OA pain. [Certain — multiple sources]
- **Orforglipron (Lilly) — ACHIEVE-2 Phase 3:** oral GLP-1 superior to dapagliflozin add-on to metformin. [Certain]
- **Teplizumab (Tzield) — expanded pediatric use, July 2026,** supported by Phase III **PROTECT** trial (328 children/adolescents 8–17 with stage 3 T1D). Aligns with the two Tzield-indication papers in our PubMed corpus. [Likely — press/secondary sources; confirm primary]
- **No new FDA diabetes drug *approvals* in the last 7 days.** Retatrutide remains unapproved (2027-or-later per trade coverage). FDA 503B semaglutide/tirzepatide compounding exclusion comment period closes 2026-07-30. [Certain]

---

## Recommended Actions

1. **Re-run the two stalled baseline pipelines** — highest priority:
   - `python baseline_clinical_trials.py`
   - `python baseline_pubmed_alerts.py`
   Then re-run `python hub_monitor.py` to regenerate diffs. Until then, all trial/PubMed findings above are 12 days old.
2. **Investigate why they stopped** — `agent_state.json` and the gap runner kept firing through 07-27/07-28, so the scheduler is alive; the two baseline jobs are failing selectively. Check their logs.
3. **Fix the `therapy_hits = 0` counter bug** — key-therapy papers are present in `papers` but the aggregate counts read 0. Verify when re-running `baseline_pubmed_alerts.py`.
4. **Update the tracker** with the newly-visible key-org Phase 3 trials once fresh data lands — especially Vertex VX-880 (NCT06832410), Lilly baricitinib T1D pair (NCT07222332 / NCT07222137), and Sanofi teplizumab (NCT07088068).
5. **Review the triple-domain paper** [42459945] (algorithmic discrimination in pediatric T1D) — direct fit for Tier 1 AI/ML + Health Equity; candidate for a synthesis note.
6. **Verify the top gaps** with combined-term PubMed searches before treating them as real — start with Beta Cell Regen × Health Equity and Drug Repurposing × Health Equity (best Tier 1 alignment). Keep at BRONZE until a second source confirms.
7. **Refresh the gap analysis inputs** — `literature_gap_data.json` is 11 days old; re-run `project1_literature_gap_analysis.py` after the PubMed pipeline is restored so the gap scores use current literature.

---

*Automated review run — reads only, no files modified. New external claims (retatrutide, teplizumab, orforglipron) are BRONZE pending primary-source verification per Research Doctrine.*
